company background image
TKNO

Alpha Teknova NasdaqGM:TKNO Stock Report

Last Price

US$3.55

Market Cap

US$99.7m

7D

-7.8%

1Y

-84.6%

Updated

25 Sep, 2022

Data

Company Financials +
TKNO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

TKNO Stock Overview

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally.

Alpha Teknova Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alpha Teknova
Historical stock prices
Current Share PriceUS$3.55
52 Week HighUS$28.00
52 Week LowUS$3.31
Beta0
1 Month Change-22.83%
3 Month Change-65.23%
1 Year Change-84.56%
3 Year Changen/a
5 Year Changen/a
Change since IPO-85.80%

Recent News & Updates

Shareholder Returns

TKNOUS Life SciencesUS Market
7D-7.8%-5.0%-5.2%
1Y-84.6%-35.1%-23.0%

Return vs Industry: TKNO underperformed the US Life Sciences industry which returned -35.1% over the past year.

Return vs Market: TKNO underperformed the US Market which returned -23% over the past year.

Price Volatility

Is TKNO's price volatile compared to industry and market?
TKNO volatility
TKNO Average Weekly Movement15.9%
Life Sciences Industry Average Movement9.7%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: TKNO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: TKNO's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1996240Stephen Gunstreamhttps://www.teknova.com

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.

Alpha Teknova Fundamentals Summary

How do Alpha Teknova's earnings and revenue compare to its market cap?
TKNO fundamental statistics
Market CapUS$99.72m
Earnings (TTM)-US$18.60m
Revenue (TTM)US$42.34m

2.4x

P/S Ratio

-5.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TKNO income statement (TTM)
RevenueUS$42.34m
Cost of RevenueUS$22.50m
Gross ProfitUS$19.84m
Other ExpensesUS$38.44m
Earnings-US$18.60m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.66
Gross Margin46.86%
Net Profit Margin-43.93%
Debt/Equity Ratio12.6%

How did TKNO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is TKNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TKNO?

Other financial metrics that can be useful for relative valuation.

TKNO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA-4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TKNO's PS Ratio compare to its peers?

TKNO PS Ratio vs Peers
The above table shows the PS ratio for TKNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.3x
LAB Standard BioTools
0.9xn/aUS$96.7m
CSBR Champions Oncology
2.1x17.1%US$106.8m
HBIO Harvard Bioscience
0.9x9.8%US$107.4m
CDXC ChromaDex
1.2x18.9%US$82.9m
TKNO Alpha Teknova
2.4x20.7%US$99.7m

Price-To-Sales vs Peers: TKNO is expensive based on its Price-To-Sales Ratio (2.4x) compared to the peer average (1.3x).


Price to Earnings Ratio vs Industry

How does TKNO's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Sales vs Industry: TKNO is good value based on its Price-To-Sales Ratio (2.4x) compared to the US Life Sciences industry average (3.7x)


Price to Sales Ratio vs Fair Ratio

What is TKNO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TKNO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ratio5.8x

Price-To-Sales vs Fair Ratio: TKNO is good value based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (5.8x).


Share Price vs Fair Value

What is the Fair Price of TKNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TKNO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TKNO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Alpha Teknova forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TKNO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TKNO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TKNO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TKNO's revenue (20.7% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: TKNO's revenue (20.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TKNO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Alpha Teknova performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-630.5%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: TKNO is currently unprofitable.

Growing Profit Margin: TKNO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TKNO's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TKNO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TKNO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (15.6%).


Return on Equity

High ROE: TKNO has a negative Return on Equity (-13.93%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Alpha Teknova's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TKNO's short term assets ($80.3M) exceed its short term liabilities ($11.9M).

Long Term Liabilities: TKNO's short term assets ($80.3M) exceed its long term liabilities ($36.9M).


Debt to Equity History and Analysis

Debt Level: TKNO has more cash than its total debt.

Reducing Debt: Insufficient data to determine if TKNO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TKNO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TKNO has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 102% each year.


Discover healthy companies

Dividend

What is Alpha Teknova current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TKNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TKNO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TKNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TKNO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TKNO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Stephen Gunstream (42 yo)

2.33yrs

Tenure

US$4,042,515

Compensation

Mr. Stephen Gunstream serves as a Director at Alpha Teknova Inc. since September 2020 and as its President and Chief Executive Officer since May 2020. He served as Chief Commercial Officer at Integrated DN...


CEO Compensation Analysis

Compensation vs Market: Stephen's total compensation ($USD4.04M) is above average for companies of similar size in the US market ($USD780.01K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TKNO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: TKNO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TKNO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGM:TKNO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Sep 22BuyUS$46,096Matthew LowellIndividual10,000US$4.61
24 Aug 22BuyUS$49,750J. MackowskiIndividual10,000US$4.98
15 Aug 22BuyUS$92,338Stephen GunstreamIndividual18,000US$5.13
20 May 22BuyUS$94,477Matthew LowellIndividual10,000US$9.45

Ownership Breakdown

What is the ownership structure of TKNO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,652,02112.8%
Institutions7,337,55825.7%
VC/PE Firms17,512,68561.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 99.59% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
62.34%
Telegraph Hill Partners
17,512,685$62.2m0%27.34%
6.72%
Thomas Davis
1,886,419$6.7m0%no data
6.01%
Irene Davis
1,687,140$6.0m0%no data
4.7%
Wellington Management Group LLP
1,320,568$4.7m-0.98%no data
2.55%
Nicholas Investment Partners, L.P.
715,449$2.5m-0.7%0.26%
2.34%
Millennium Management LLC
656,981$2.3m100.44%no data
2.02%
Redmile Group, LLC
567,800$2.0m0%0.07%
1.49%
BlackRock, Inc.
417,849$1.5m-0.04%no data
1.3%
Stephens Investment Management Group, LLC
365,856$1.3m0%0.03%
1.18%
Norges Bank Investment Management
330,614$1.2m0%no data
1.12%
The Vanguard Group, Inc.
313,435$1.1m-9.13%no data
1.03%
Ranger Investment Management, L.P.
288,046$1.0m2.41%0.08%
0.95%
Premier Fund Managers Limited
265,934$944.1k0%0.01%
0.89%
Pura Vida Investments, LLC
251,112$891.4k0%0.14%
0.85%
Platinum Investment Management Limited
239,594$850.6k41.57%0.03%
0.7%
Russell Investment Management, LLC
197,032$699.5k-3.32%no data
0.45%
State Street Global Advisors, Inc.
127,551$452.8k8.47%no data
0.44%
Geode Capital Management, LLC
123,572$438.7k-1.14%no data
0.43%
Parkman Healthcare Partners LLC
119,997$426.0k0.44%0.17%
0.4%
Allianz Asset Management AG
113,661$403.5k-4.06%no data
0.38%
Conestoga Capital Advisors, LLC
105,949$376.1k20.25%0.01%
0.38%
Grandeur Peak Global Advisors, LLC
105,814$375.6k-53.42%0.01%
0.33%
Allspring Global Investments, LLC
92,843$329.6k-70.66%no data
0.32%
AWM Investment Company Inc
90,000$319.5k50%0.05%
0.29%
Victory Capital Management Inc.
80,471$285.7k-0.01%no data

Company Information

Alpha Teknova, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Alpha Teknova, Inc.
  • Ticker: TKNO
  • Exchange: NasdaqGM
  • Founded: 1996
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$99.721m
  • Shares outstanding: 28.09m
  • Website: https://www.teknova.com

Number of Employees


Location

  • Alpha Teknova, Inc.
  • 2290 Bert Drive
  • Hollister
  • California
  • 95023
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TKNONasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/25 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.